Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1200/jco.2004.05.113 | FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study |
| https://doi.org/10.1056/nejmoa0910383 | Adjuvant Trastuzumab in HER2-Positive Breast Cancer |
| https://doi.org/10.1093/jnci/djj052 | Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis |
| https://doi.org/10.1093/jnci/djj329 | Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer |
| https://doi.org/10.1158/1078-0432.ccr-06-2765 | Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series |
| https://doi.org/10.1158/1078-0432.ccr-07-4756 | Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes |
| https://doi.org/10.1016/s1470-2045(14)70069-5 | Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data |
| https://doi.org/10.1056/nejm199503093321002 | The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer |
| https://doi.org/10.1093/biostatistics/1.1.49 | The validation of surrogate endpoints in meta-analyses of randomized experiments |
| https://doi.org/10.1016/s1470-2045(17)30717-9 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial |
| https://doi.org/10.1016/s1470-2045(15)00551-3 | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial |
| https://doi.org/10.1158/0008-5472.sabcs-09-62 | Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. |
| https://doi.org/10.2307/2533853 | Criteria for the Validation of Surrogate Endpoints in Randomized Experiments |
| https://doi.org/10.1016/s0140-6736(00)02528-9 | Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis |
| https://doi.org/10.1093/jnci/djm024 | Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials |
| https://doi.org/10.1200/jco.2007.11.8836 | Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer |
| https://doi.org/10.1038/nrclinonc.2010.43 | Biomarkers and surrogate end points—the challenge of statistical validation |
| https://doi.org/10.1016/s1470-2045(15)00051-0 | Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial |
| https://doi.org/10.1093/jnci/djy018 | Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis |
| https://doi.org/10.1016/s1470-2045(11)70259-5 | Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial |
| https://doi.org/10.4103/2229-3485.159943 | Common pitfalls in statistical analysis: Clinical versus statistical significance |
| https://doi.org/10.1002/sim.3923 | Generalized pairwise comparisons of prioritized outcomes in the two‐sample problem |
| https://doi.org/10.1200/jco.18.01624 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial |
| https://doi.org/10.1111/1467-9876.00244 | Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points |
| https://doi.org/10.1002/pst.207 | Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation |
| https://doi.org/10.1016/s1470-2045(11)70231-5 | HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data |
| https://doi.org/10.1200/jco.22.02774 | FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study |
| https://doi.org/10.1002/(sici)1097-0258(19991230)18:24<3435::aid-sim365>3.0.co;2-o | The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials |
| https://doi.org/10.1093/jnci/djt270 | Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis |
| https://doi.org/10.1177/1740774507087554 | Ensuring trial validity by data quality assurance and diversification of monitoring methods |
| https://doi.org/10.1016/s1470-2045(09)70023-3 | Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data |
| https://doi.org/10.1136/bmj.f457 | Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study |
| https://doi.org/10.1007/s10549-009-0512-0 | The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial |
| https://doi.org/10.1093/jnci/djm287 | Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial |
| https://doi.org/10.1016/j.jval.2016.10.011 | Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward |
| https://doi.org/10.1093/annonc/mdp523 | Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature |
| https://doi.org/10.1586/erm.10.120 | Integrating biomarkers in clinical trials |
| https://doi.org/10.1186/1471-2164-9-394 | Comparison of prognostic gene expression signatures for breast cancer |
| https://doi.org/10.1200/jco.2016.66.6693 | HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials |
| https://doi.org/10.1002/bimj.201400049 | Statistical evaluation of surrogate endpoints with examples from cancer clinical trials |
| https://doi.org/10.1200/jco.2006.10.4380 | Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer |
| https://doi.org/10.1002/(sici)1097-0258(19991230)18:24<3435::aid-sim365>3.3.co;2-f | The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials |
| https://doi.org/10.1200/jco.2013.31.18_suppl.lba4001 | Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. |
| https://doi.org/10.1016/s1470-2045(21)00584-2 | Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study |
| https://doi.org/10.1093/annonc/mdy214 | Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial |
| https://doi.org/10.1007/s10549-012-2045-1 | Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study |
| https://doi.org/10.1016/s1470-2045(14)70025-7 | Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial |
| https://doi.org/10.1177/1740774512447898 | A statistical approach to central monitoring of data quality in clinical trials |
| https://doi.org/10.1016/j.ejca.2010.12.015 | Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 |
| https://doi.org/10.1056/nejmp1411794 | Data Sharing, Year 1 — Access to Data from Industry-Sponsored Clinical Trials |
| https://doi.org/10.1080/2162402x.2015.1026529 | Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients |
| https://doi.org/10.2217/fon-2019-0209 | A Phase III Open-Label Trial to Evaluate Efficacy and Safety of CPI-613 Plus Modified FOLFIRINOX (MFFX) versus FOLFIRINOX (FFX) in Patients with Metastatic Adenocarcinoma of the Pancreas |
| Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study | |
| https://doi.org/10.1038/nrclinonc.2017.8 | Precision medicine needs randomized clinical trials |
| https://doi.org/10.1200/jco.22.02241 | Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer |
| https://doi.org/10.1016/j.ophtha.2013.02.016 | Stereotactic Radiotherapy for Neovascular Age-related Macular Degeneration |
| https://doi.org/10.1016/j.ejca.2013.07.003 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study |
| https://doi.org/10.1007/s10549-013-2444-y | Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) |
| https://doi.org/10.1200/jco.19.00858 | Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 |
| https://doi.org/10.1016/s1470-2045(18)30750-2 | Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis |
| https://doi.org/10.1111/biom.12245 | On the Relationship between the Causal-Inference and Meta-Analytic Paradigms for the Validation of Surrogate Endpoints |
| https://doi.org/10.1001/jamaoncol.2015.6359 | The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials |
| https://doi.org/10.1007/s11060-016-2094-0 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial |
| https://doi.org/10.1186/s13054-014-0648-0 | Prehospital identification of trauma patients with early acute coagulopathy and massive bleeding: results of a prospective non-interventional clinical trial evaluating the Trauma Induced Coagulopathy Clinical Score (TICCS) |
| https://doi.org/10.1056/nejmp1610336 | Data Sharing — Is the Juice Worth the Squeeze? |
| https://doi.org/10.1093/oncolo/oyac006 | Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy |
| https://doi.org/10.1038/nrd.2016.81 | Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework |
| https://doi.org/10.1200/jco.22.02363 | Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy |
| https://doi.org/10.1186/s13045-016-0322-x | Proceedings of the 2016 China Cancer Immunotherapy Workshop |
| https://doi.org/10.1136/bmjopen-2012-001802 | Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials |
| https://doi.org/10.1016/j.ophtha.2023.02.001 | A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration |
| https://doi.org/10.1007/978-1-4614-0140-7_5 | On Stopping a Randomized Clinical Trial for Futility |
| https://doi.org/10.1186/s13690-021-00656-7 | Disability and COVID-19: ensuring no one is left behind |
| https://doi.org/10.1371/journal.pone.0066848 | Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer |
| https://doi.org/10.1001/jamaoncol.2022.3755 | Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer |
| https://doi.org/10.3390/cancers13215286 | Comparison of 68Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer |
| https://doi.org/10.1007/s10549-014-3221-2 | Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study |
| https://doi.org/10.1111/iej.13895 | What ultimately matters in root canal treatment success and tooth preservation: A 25‐year cohort study |
| https://doi.org/10.1016/s1470-2045(24)00218-3 | The tyranny of non-inferiority trials |
| https://doi.org/10.1200/jco.23.01535 | Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer |
| https://doi.org/10.1016/j.jclinepi.2021.03.018 | The Net Benefit of a treatment should take the correlation between benefits and harms into account |
| https://doi.org/10.1200/jco.22.02915 | Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018) |
| https://doi.org/10.1016/j.jacc.2023.06.047 | Generalized Pairwise Comparisons to Assess Treatment Effects |
| https://doi.org/10.1002/bimj.202100354 | Generalized pairwise comparisons for censored data: An overview |
| https://doi.org/10.1001/jamaoncol.2025.2026 | Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer |
| https://doi.org/10.1016/j.eururo.2024.04.038 | Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials |
| https://doi.org/10.1038/s41422-024-01026-y | The 1% gift to humanity: The Human Genome Project II |
| https://doi.org/10.1016/s1470-2045(24)00648-x | Dose optimisation to improve access to effective cancer medicines |
| https://doi.org/10.1016/j.jcpo.2025.100647 | Central and Eastern Europe: A crucible for clinical cancer innovation? |
| https://doi.org/10.1053/jhep.2003.50474 | A Pilot Study of Therapeutic Vaccination With Envelope Protein E1 in 35 Patients With Chronic Hepatitis C |
| https://doi.org/10.1002/(sici)1097-0258(19961230)15:24<2797::aid-sim290>3.0.co;2-v | ON THE RELATIONSHIP BETWEEN RESPONSE TO TREATMENT AND SURVIVAL TIME |
| https://doi.org/10.1016/s0197-2456(02)00236-2 | Statistical challenges in the evaluation of surrogate endpoints in randomized trials |
| https://doi.org/10.1016/s0093-7754(01)90247-7 | Should Dukes' B patients receive adjuvant therapy? A statistical perspective |
| https://doi.org/10.1016/s0197-2456(00)00069-6 | Fraud in Medical Research |
| https://doi.org/10.1200/jco.2004.06.924 | Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step |
| https://doi.org/10.1002/sim.923 | Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes |
| https://doi.org/10.1038/449180a | The road to recovery |
| https://doi.org/10.1245/aso.2006.07.003 | Current Issues in Adjuvant Treatment of Stage II Colon Cancer |
| https://doi.org/10.1111/j.1467-985x.2004.00293.x | The Validation of Surrogate End Points by using Data from Randomized Clinical Trials: A Case-Study in Advanced Colorectal Cancer |
| https://doi.org/10.1093/annonc/mdl173 | Alternative clinical end points in rectal cancer—are we getting closer? |